Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 2.11
-2.31 %
$ 13.9 M
Market Cap
17.58
P/E
1. INTRINSIC VALUE
Balance Sheet
Intelligent Bio Solutions Inc.
| Current Assets | 8.53 M |
| Cash & Short-Term Investments | 6.3 M |
| Receivables | 978 K |
| Other Current Assets | 1.25 M |
| Non-Current Assets | 5.24 M |
| Long-Term Investments | 0 |
| PP&E | 873 K |
| Other Non-Current Assets | 4.37 M |
| Current Liabilities | 5.45 M |
| Accounts Payable | 602 K |
| Short-Term Debt | 1.06 M |
| Other Current Liabilities | 3.78 M |
| Non-Current Liabilities | 145 K |
| Long-Term Debt | 81.3 K |
| Other Non-Current Liabilities | 63.6 K |
EFFICIENCY
Earnings Waterfall
Intelligent Bio Solutions Inc.
| Revenue | 3.11 M |
| Cost Of Revenue | 1.69 M |
| Gross Profit | 1.43 M |
| Operating Expenses | 11.7 M |
| Operating Income | -10.3 M |
| Other Expenses | -92.2 K |
| Net Income | -10.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Intelligent Bio Solutions Inc.
| Net Income | -10.2 M |
| Depreciation & Amortization | 1.21 M |
| Capital Expenditures | -221 K |
| Stock-Based Compensation | 230 K |
| Change in Working Capital | -702 K |
| Others | -258 K |
| Free Cash Flow | -9.79 M |
Wall Street Analysts Price Targets
Intelligent Bio Solutions Inc.
INBS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
INBS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Intelligent Bio Solutions Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Oct 04, 2023
|
Bought
5 K USD
|
TOWERS CHRISTOPHER
Director
|
+ 9090
|
0.55 USD |
|
1 year ago
Oct 04, 2023
|
Bought
0 USD
|
TOWERS CHRISTOPHER
Director
|
+ 9090
|
0 USD |
|
1 year ago
Oct 04, 2023
|
Bought
0 USD
|
TOWERS CHRISTOPHER
Director
|
+ 9090
|
0 USD |
|
1 year ago
Oct 04, 2023
|
Bought
62 K USD
|
Sakiris Spiro Kevin
Chief Financial Officer
|
+ 112727
|
0.55 USD |
|
1 year ago
Oct 04, 2023
|
Bought
0 USD
|
Sakiris Spiro Kevin
Chief Financial Officer
|
+ 112727
|
0 USD |
|
1 year ago
Oct 04, 2023
|
Bought
0 USD
|
Sakiris Spiro Kevin
Chief Financial Officer
|
+ 112727
|
0 USD |
|
1 year ago
Sep 01, 2023
|
Bought
92.5 USD
|
Simeonidis Harry
CEO
|
+ 50
|
1.85 USD |
|
1 year ago
Aug 31, 2023
|
Bought
192 USD
|
Simeonidis Harry
CEO
|
+ 100
|
1.92 USD |
7. News
Intelligent Bio Solutions Inc. Announces Pricing of $2.6 Million Public Offering of Common Stock
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the pricing of its previously announced underwritten public offering of 1,304,348 shares of common stock at a public offering price of $2.00 per share of common stock, for gross proceeds of approximately $2.6 million, before deducting underwriting discounts and commissions and offering expenses.
globenewswire.com
- 1 week ago
Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
globenewswire.com
- 1 week ago
Intelligent Bio Solutions Announces Fiscal Q2 2025 Financial Results and Key Operational Achievements
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion dollar U.S. market in 2025 Added strategic partnerships, increasing visibility across the Asia-Pacific Region and the U.S. Secured 19 accounts during quarter, adding to 400+ active customer accounts in 19 countries NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for the fiscal second quarter and six months ended December 31, 2024, and provided a business update. "Fiscal Q2 was a successful quarter for the business in a number of areas.
globenewswire.com
- 2 weeks ago
Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy
Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025 Company highlights key milestones achieved in 2024, growing revenues and progress towards U.S. expansion in 2025
globenewswire.com
- 3 weeks ago
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
Avon Freight Group selects INBS' fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency
globenewswire.com
- 3 weeks ago
Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales
Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, 2024 Higher-margin cartridge sales driving profitability and long-term growth Expanding U.S. and international market presence with FDA submission and strategic partnerships NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its preliminary unaudited selected financial results for the fiscal second quarter and six months ended December 31, 2024. For the fiscal 2025 second quarter and six-month period, the Company anticipates: Unaudited revenue of approximately $0.61 million for the three months ended December 31, 2024.
globenewswire.com
- 3 weeks ago
Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade
Multilingual upgrade will make INBS' Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas, Europe, Asia and the Middle East, supporting its strategic global expansion goals and planned 2025 entry into the US market. Multilingual upgrade will make INBS' Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas, Europe, Asia and the Middle East, supporting its strategic global expansion goals and planned 2025 entry into the US market.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing
Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screening
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites
Princebuild has moved from saliva testing to INBS' fingerprint drug testing solution to implement a more streamlined, in-house solution across seven sites.
globenewswire.com
- 1 month ago
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the US Food and Drug Administration (FDA) for clearance following FDA review of its Intelligent Fingerprinting Drug Screening System (the "System"), an innovative, rapid and pain-free method for drug screening. The submission represents a critical milestone on the Company's path to realizing its goal of entering the US market with its drug testing solution in 2025.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it will host a virtual fireside chat with Harry Simeonidis, President & CEO and Spiro Sakiris, CFO at 4:30 p.m. ET on December 11, 2024.
globenewswire.com
- 2 months ago
Intelligent Bio Solutions to Participate in the Noble Capital Markets' 20th Annual Emerging Growth Equity Conference
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will present at the upcoming Noble Capital Markets' 20th Annual Emerging Growth Equity Conference on December 3-4, 2024, in Boca Raton, FL.
globenewswire.com
- 3 months ago
8. Profile
Summary
Intelligent Bio Solutions Inc. INBS
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 13.9 M
Dividend Yield
0.00%
Description
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Contact
142 West 57th Street, New York, NY, 10019
https://gbs.inc
IPO
Date
Dec. 23, 2020
Employees
50
Officers
Callistus Sequeira
Vice President of Global Quality & Operations
Anna Turkington
Vice President of Marketing
Mr. Harry Simeonidis
President & Chief Executive Officer
Mr. Doug Heath
Vice President of Global Sales
Mr. Alex Arzeno
Vice President of Investor Relations
Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law
Chief Financial Officer